UNSPSC 51182405: Dibase calcium phosphate

This classification denotes a calcium phosphate and calcium supplement with the molecular formula Ca.HO4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L11K75P92J, chemically known as phosphoric acid, calcium salt (1:1) but generally known as calcium phosphate, dibasic, which bears US NIH Compound Identifier 24441. European Medicines Agency schedules Calcium phosphate, dibasic in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13192MIG. SMILES: OP(=O)([O-])[O-].[CA+2].

UNSPSC 51182405 Dibase calcium phosphate is a Commodity code that reflects state and local procurement activity centered on pharmaceutical and clinical laboratory supplies rather than the specific chemical compound its name suggests. Recent solicitations show state and local governments purchasing drug testing services, pharmaceutical distribution agreements, and generic medication supplies through competitive procurements. The issuing bodies include county criminal justice departments, state health and human services commissions, and multistate cooperative purchasing alliances representing participating state and local agencies. Scope varies widely: Collin County's RFP encompasses specimen collection staffing, immunoassay screening with confirmatory testing (LC/MS/MS or GC/MS), oral fluid and hair testing alternatives, and electronic result reporting for approximately 25,031 annual offender drug tests, while the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) procurement solicits manufacturers of generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers to state and local facilities across Minnesota, Oregon, and other participating jurisdictions.

Activity is concentrated in Texas and Minnesota. Collin County's offender specimen collection and drug testing services RFP (2026-327) has a response deadline of July 23, 2026, with an estimated contract value of $600,000 and a two-year term commencing September 1, 2026, plus three optional one-year renewal periods. The anticipated award date is August 10, 2026. MMCAP's generic pharmaceuticals and OTC products RFP (S1070000015802) closed with proposals due March 26, 2026, and awards effective July 1, 2026, for a two-year initial term with optional extensions through June 30, 2028. The Texas Health and Human Services Commission's RFI (HHS0017013) on direct-to-manufacturer prescription programs, posted April 3, 2026, represents preliminary market intelligence gathering and does not specify funding, timelines, or formal evaluation criteria. All three procurements require vendors to demonstrate lab certification, FDA compliance, cGMP and DSCSA compliance, or direct contracting capacity with self-insured employers and government entities.